Literature DB >> 19224842

The marriage of growth factor inhibitors and chemotherapy: bliss or bust?

Stephen Staal, Michael J O'Connell, Carmen J Allegra.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19224842     DOI： 10.1200/JCO.2008.20.3224

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.

Authors:  Marlies H G Langenberg; Petronella O Witteveen; Nienke A G Lankheet; Jeanine Ml Roodhart; Hilde Rosing; Ingeborg J G M van den Heuvel; Jos H Beijnen; Emile E Voest
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

2.  Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.

Authors:  Katharina Pachmann; O Camara; T Kroll; M Gajda; A K Gellner; J Wotschadlo; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-08       Impact factor: 4.553

3.  Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1.

Authors:  Barbara Jonchère; Alexandra Vétillard; Bertrand Toutain; David Lam; Anne Charlotte Bernard; Cécile Henry; Sophie De Carné Trécesson; Erick Gamelin; Philippe Juin; Catherine Guette; Olivier Coqueret
Journal:  Oncotarget       Date:  2015-01-01

4.  Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis.

Authors:  Alexandra Vétillard; Barbara Jonchère; Marie Moreau; Bertrand Toutain; Cécile Henry; Simon Fontanel; Anne-Charlotte Bernard; Mario Campone; Catherine Guette; Olivier Coqueret
Journal:  Oncotarget       Date:  2015-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.